Oct 2026· Frontiers in Endocrinology· Vol 17· 0 citations· 54 references
Medicine
TL;DR
This review evaluates pharmacogenomic evidence across monogenic and polygenic diabetes subtypes, presents Indian clinical case studies demonstrating the consequences of genomic misclassification, and positions GLIS3 as an underexplored regulatory gene with cross-disease relevance spanning neonatal diabetes, Type 1, and Type 2 diabetes.
Abstract
Background Diabetes mellitus encompasses a heterogeneous group of metabolic disorders with a significant genetic basis that current standardized treatment protocols fail to adequately address. Type 2 diabetes in particular is driven by genetic factors that operate independently of lifestyle, with a substantial proportion of patients in South Asian populations developing the disease despite normal body weight and healthy habits. India presents a uniquely important context for pharmacogenomic research given its extraordinary population stratification across tribal, linguistic, religious, and geographic groups creating a genetic landscape that Western genomic data cannot adequately represent. Objective This review evaluates pharmacogenomic evidence across monogenic and polygenic diabetes subtypes, presents Indian clinical case studies demonstrating the consequences of genomic misclassification, and positions GLIS3 as an underexplored regulatory gene with cross-disease relevance spanning neonatal diabetes, Type 1, and Type 2 diabetes. It further examines the potential for expanded clinical implementation of genotype-guided therapy, particularly in genetically diverse populations. Key insights GLIS3 encodes a zinc finger transcription factor that governs beta-cell development, insulin gene transcription, and endoplasmic reticulum stress protection by functioning as a master regulator of beta-cell survival rather than acting through a single pathway. Its association across multiple diabetes subtypes, combined with emerging evidence of population-specific variants in Indian cohorts, positions it as a compelling future pharmacogenomic target. However, no GLIS3-directed clinical testing or therapy is currently available, and its pharmacogenomic utility remains hypothetical pending prospective validation. Indian pharmacogenomic data further reveal 76 known variants affecting antidiabetic drug response, with higher frequencies of poor metformin response alleles compared to global population findings with immediate clinical implications for one of the world’s highest diabetes-burden nations. Conclusion Realizing the potential of precision medicine in diabetes requires population-specific genomic research, integration of pharmacogenomic testing into national health schemes such as Ayushman Bharat, development of AI-driven clinical decision tools, and policy frameworks guided by bodies such as ICMR. Genotype-guided therapy represents an emerging clinical priority with the potential to improve outcomes in genetically diverse populations where standardized protocols may be suboptimal.
BACKGROUND
Gestational diabetes mellitus (GDM) complicates roughly one in seven pregnancies and predicts later maternal type 2 diabetes mellitus (T2DM). Yet its pharmacological management still rests on a handful of agents (insulin, metformin and glibenclamide), none of them selected on the basis of the disease's molec...
Wael M. Osman· Diabetes, obesity and metabo...· 0 citations
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by immune-mediated destruction of pancreatic β-cells, resulting in absolute insulin deficiency and lifelong dependence on exogenous insulin. This disease, if not treated, leads to acute and chronic complications affecting the cardiovascular, renal,...
A narrative review summarizes the current knowledge on the genetic architecture of pediatric obesity, explores the transition from gene discovery to precision medicine, discusses available diagnostic algorithms and genetic testing strategies, and proposes an updated diagnostic flowchart.
Cristina Partenope, I. Rabbone, R. Pajno· Medicina· 0 citations
Aims/Hypothesis: Atypical forms of diabetes often provide diagnostic challenges and are suboptimally treated. We sought to determine whether type 1 and 2 diabetes polygenic scores (PS) would help improve classification of islet autoantibody-negative (IAb-) atypical diabetes cases. Methods: We implemented type 1 diabete...
Steven D. Gage, R. Kreienkamp, Aaron J. Deutsch et al.· medRxiv· 0 citations
Type 2 diabetes mellitus (T2D) represents over 90% of diabetes cases globally, posing a growing public health crisis with an estimated 783 million adults projected to be affected by 2045. This condition arises from a complex interplay of insulin resistance, progressive pancreatic β-cell dysfunction, and chronic low-gra...
R. Araújo, G. Ortiz-Cruz, S. Nupo et al.· Nutrients· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.